The researchers loaded the platform with two pairs of drugs approved by the FDA: BRAF and MEK inhibitors used to treat melanoma (skin cancer) with a BRAF gene mutation (present in 50% of melanoma ...

For instance, a study on the use of BRAF-MEK inhibitors in patients with papillary craniopharyngiomas demonstrated promising results, with a significant percentage of patients showing a durable ...

The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.

KRAS mutation in endothelial cells activates the MEK/ERK pathway, but has no direct effect on PI3k. Subsequently, KRAS/BRAF activates the Notch pathway or TGFb/BMP pathway through the MEK/ERK ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management ...

NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition (NCT06299839). About Pasithea Therapeutics Corp. Pasithea is a biotechnology company focused on the discovery, research and ...

tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumours with a documented RAS, NF1 or RAF mutation or ...